Pharmaceuticals

JW Therapeutics Announces IND Approval for the Clinical Trial of Relma-cel in Patients with Moderately or Severely Refractory Systemic Lupus Erythematosus

SHANGHAI, April 10, 2023 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that it has received the Investigational New Drug (IND) clearance from the Na...

2023-04-10 19:30 2722

China's First Nectin-4 Targeted ADC 9MW2821 Clinical Progress Released

SHANGHAI, April 6, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the whole industry chain layout, announced its Nectin-4 targeted site-specific ADC asset (R&D code: 9MW2821) demonstrated promising clinical data. The preliminary data show positive therapeut...

2023-04-07 16:34 4205

Cooperation Agreement Concluded between BioKangtai and Biotis

-- Indicating Technology Transfer of the World's First Dual-carrier 13-valent Pneumococcal Conjugate Vaccine toIndonesia SHENZHEN, China, April 7, 2023 /PRNewswire/ -- On the morning of April 5, Beijing Minhai Biotechnology Co., Ltd. (hereinafter referred to as "BioMinhai"), a wholly-owned subsi...

2023-04-07 10:41 3538

Nuance Pharma Announces Dosing of First Patient in ENHANCE - China Phase III Trial for Chronic Obstructive Pulmonary Disease ("COPD")

SHANGHAI, April 6, 2023 /PRNewswire/ -- Nuance Pharma ("the Company") announces dosing of first patient in the ENHANCE - China Phase III Trial for the maintenance treatment of chronic obstructive pulmonary disease ("COPD") of its novel solution Ensifentrine in mainlandChina. Ensifentrine is a fi...

2023-04-07 10:00 1880

Everest Medicines Announces New Drug Application Acceptance by Singapore HSA for Nefecon for the Treatment of Primary IgA Nephropathy

Nefecon NDA is currently under Priority Review in China and expected to receive approval in 2H 2023 SHANGHAI, April 6, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, ...

2023-04-06 07:30 2312

BIORCHESTRA Expands Executive Leadership Team with the Appointment of David Oxley as Chief Business Officer

CAMBRIDGE, Mass. and DAEJEON, South Korea, April 5, 2023 /PRNewswire/ --  BIORCHESTRA , a biotherapeutics company focused on the treatment of rare and degenerative diseases within the Central Nervous System (CNS) leveraging the Biorchestra Drug Delivery System (BDDSTM), w...

2023-04-05 20:00 1990

Bridgewest Group launches NovaCina, new sterile injectable CDMO

MIAMI and PERTH, Australia, April 5, 2023 /PRNewswire/ -- Global private investment firm,Bridgewest Group, recognized for developing innovative companies in life sciences, software, and deep tech, launches new Contract Development and Manufacturing Organization (CDMO) focused on sterile injectabl...

2023-04-05 09:41 2027

Goodwin Biotechnology Inc. (GBI) Announces First Commercial Contract Signing

PLANTATION, Fla., April 4, 2023 /PRNewswire/ -- GBI proudly announces the signing of their first Master Supply Agreement for commercializing an antibody. With the development of this new partnership, GBI's integrated CDMO biologics services will showcase their expertise in bringing a product from...

2023-04-04 20:57 2072

Biosion Initiates Phase II Clinical Trial of BSI-045B in Atopic Dermatitis

NEWARK, Del. and NANJING, China, April 4, 2023 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a global clinical-stage R&D biotechnology company, today announced that it has successfully opened an IND following review by the U.S. Food and Drug Administration toinitiate a Phase 2 clinical trial of BS...

2023-04-04 20:50 1710

Lynk Pharmaceuticals Announces Positive Results for LNK01003 in Phase I Trial in Healthy Subjects

HANGZHOU, China, April 4, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that it has recently completed phase I trials in healthy subjects inChina for its self-developed innovative intestina...

2023-04-04 20:00 2684

Latest Updates of 6 Viva's Portfolio Companies

HONG KONG, April 4, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the suc...

2023-04-04 19:39 2226

Cambrex Opens New Stability Storage Facility in Belgium

EAST RUTHERFORD, N.J., April 4, 2023 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced that their stability storage business, Q1 Sc...

2023-04-04 15:00 1858

Bridgewest Group completes acquisition of sterile injectable manufacturing plant in Western Australia from Pfizer

MIAMI and PERTH, Australia, April 4, 2023 /PRNewswire/ -- Global private investment firm,Bridgewest Group, recognized for developing innovative companies in life sciences, software, and deep tech, announces that it has completed the acquisition of thePerth sterile injectable manufacturing facilit...

2023-04-04 10:00 2643

BioDuro-Sundia Wins Life Sciences Review Top 10 BPO Award

IRVINE, Calif., April 4, 2023 /PRNewswire/ -- Life Sciences Review magazine recognizes BioDuro-Sundia as top 10 Business Process Outsourcing (BPO). BioDuro-Sundia earned this award for its high-quality service and cutting-edge technology, as well as its integrated contract research, development a...

2023-04-04 08:30 2355

Lynk Pharmaceuticals Announces Positive Results for LNK01003 in Phase I Trial in Healthy Subjects

HANGZHOU, China, April 4, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that it has recently completed phase I trials in healthy subjects inChina for its self-developed innovative intestina...

2023-04-04 08:00 2486

GC Cell and New Management Embarking on a New Chapter

* Securing future growth engine by scouting global talents; AGM resolved new CEOJames Park and CTO Ho-won Kim as internal directors * Setting business goals focusing on change and growth * Proposing a new corporate vision of "Global Creator of Cell & Gene Therapy" YONGIN,South Korea, April 3...

2023-04-03 16:47 2026

Harbour BioMed Reports Full Year 2022 Financial Results

CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands, April 3, 2023 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncolo...

2023-04-03 15:10 3379

The World's Second Approved Biosimilars of Denosumab (MAILISHU)

SHANGHAI, April 3, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, announced that the Denosumab solution for injection (trade name: MAILISHU, project code: 9MW0311), which is developed by its wholly-owned subsidiary T-m...

2023-04-03 13:44 1752

CBC Group Appoints Healthcare Veteran Abbas Hussain as Operating Partner

SINGAPORE, March 31, 2023 /PRNewswire/ -- Singapore-headquartered asset management firm, CBC Group ("CBC"), is pleased to announce the appointment of healthcare industry veteran, Abbas Hussain, as Operating Partner. In this role, Abbas will closely partner with CBC's business teams to identify, ...

2023-04-01 10:00 3405

Henlius 2022 Annual Results: Significant Achievements in Commercialisation, Surged to RMB3.2 Billion in Revenues

SHANGHAI, April 1, 2023 /PRNewswire/ -- Henlius (2696.HK) announced its 2022 annual results. In 2022, Henlius' revenue reached aboutRMB3.2147 billion, representing an increase of 91.1% YoY, primarily due to sales revenue and licensing revenue generated by the successive commercialisation of vario...

2023-04-01 00:06 8748
1 ... 73747576777879 ... 294